Clinical Trial

Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer

Study acronym: ORION
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This will be assessed using a 5-year cost-utility analysis based on data from the clinical trial and the National Health Data System (NHDS).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-19; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2026-03-17
Trial Details
NCT Number NCT07189598
Lead Sponsor Center Eugene Marquis
Conditions High Risk Prostate Cancer
Enrollment 390 participants
Start Date 2026-03-02
Primary Completion 2033-04-01 (estimated)
Study Completion 2033-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-30